Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers

被引：36

作者：

Rescigno, Pasquale ^{[1
,2
]}

Lorente, David ^{[3
]}

Dolling, David ^{[1
]}

Ferraldeschi, Roberta ^{[1
]}

Rodrigues, Daniel Nava ^{[1
]}

Riisnaes, Ruth ^{[1
]}

Miranda, Susana ^{[1
]}

Bianchini, Diletta ^{[1
]}

Zafeiriou, Zafeiris ^{[1
]}

Sideris, Spyridon ^{[1
]}

Ferreira, Ana ^{[1
]}

Figueiredo, Ines ^{[1
]}

Sumanasuriya, Semini ^{[1
]}

Mateo, Joaquin ^{[1
]}

Perez-Lopez, Raquel ^{[1
]}

Sharp, Adam ^{[1
]}

Tunariu, Nina ^{[1
]}

de Bono, Johann S. ^{[1
]}

机构：

[1] Inst Canc Res, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England

[2] AOU Federico II, Dept Translat Med Sci, Dept Clin Med & Surg, Naples, Italy

[3] Hosp Univ La Fe, Med Oncol Serv, Valencia, Spain

来源：

EUROPEAN UROLOGY ONCOLOGY | 2018年 / 1卷 / 01期

关键词：

Prostate cancer; PTEN; ERG; Docetaxel; FUSION; TMPRSS2-ERG; EXPRESSION; DELETION;

D O I：

10.1016/j.euo.2018.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Loss of PTEN is a common genomic aberration in castration-resistant prostate cancer (CRPC) and is frequently concurrent with ERG rearrangements, causing resistance to next-generation hormonal treatment (NGHT) including abiraterone. The relationship between PTEN loss and docetaxel sensitivity remains uncertain. Objective: To study the antitumor activity of docetaxel in metastatic CRPC in relation to PTEN and ERG aberrations. Design, setting, and participants: Single-centre, retrospective analysis of PTEN loss and ERG expression using a previously described immunohistochemistry (IHC) binary classification system. Patients received docetaxel between January 1, 2006 and July 31, 2016. Outcome measurements and statistical analysis: Response correlations were analyzed using Pearson's chi(2) tests and independent-sample t tests. Overall (OS) and progressionfree survival (PFS) were analyzed using univariate and multivariate (MVA) Cox regression and Kaplan-Meier methods. Results and limitations: Overall, 215 patients were eligible. Established metastatic CRPC prognostic factors were well balanced between PTEN loss (39%) and normal patients (61%). PTEN loss was associated with shorter median OS (25.4 vs 34.7 mo; hazard ratio [HR] 1.66, 95% confidence interval [CI] 1.18-2.13; p = 0.001). There were no differences in median PFS (8.0 vs 9.1 mo; univariate HR 1.20, 95% CI 0.86-1.68; p = 0.28) and PSA response (53.4% vs 50.6%; p = 0.74). PTEN loss was an independent prognostics factor in MVA. ERG status was available for 100 patients. ERG positivity was not associated with OS or PFS. Limitations include the retrospective nature and the single-centre analysis. Conclusions: Our findings suggest that metastatic CRPC with PTEN loss might benefit more from docetaxel than from NGHT. Patient summary: In this study we found that metastatic prostate cancer with loss of the PTEN switch may benefit more from docetaxel than from abiraterone. (C) 2018 European Association of Urology. Published by Elsevier B.V.

引用

页码：71 / 77

页数：7

共 29 条

[1] An Immunohistochemical Signature Comprising PTEN, MYC, and Ki67 Predicts Progression in Prostate Cancer Patients Receiving Adjuvant Docetaxel After Prostatectomy [J].

Antonarakis, Emmanuel S. ;

Keizman, Daniel ;

Zhang, Zhe ;

Gurel, Bora ;

Lotan, Tamara L. ;

Hicks, Jessica L. ;

Fedor, Helen L. ;

Carducci, Michael A. ;

De Marzo, Angelo M. ;

Eisenberger, Mario A. .

CANCER, 2012, 118 (24) :6063-6071

[2] Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer [J].

Attard, G. ;

Clark, J. ;

Ambroisine, L. ;

Fisher, G. ;

Kovacs, G. ;

Flohr, P. ;

Berney, D. ;

Foster, C. S. ;

Fletcher, A. ;

Gerald, W. L. ;

Moller, H. ;

Reuter, V. ;

De Bono, J. S. ;

Scardino, P. ;

Cuzick, J. ;

Cooper, C. S. .

ONCOGENE, 2008, 27 (03) :253-263

[3] Prostate cancer [J].

Attard, Gerhardt ;

Parker, Chris ;

Eeles, Ros A. ;

Schroder, Fritz ;

Tomlins, Scott A. ;

Tannock, Ian ;

Drake, Charles G. ;

de Bono, Johann S. .

LANCET, 2016, 387 (10013) :70-82

[4] Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer [J].

Carver, Brett S. ;

Chapinski, Caren ;

Wongvipat, John ;

Hieronymus, Haley ;

Chen, Yu ;

Chandarlapaty, Sarat ;

Arora, Vivek K. ;

Le, Carl ;

Koutcher, Jason ;

Scher, Howard ;

Scardino, Peter T. ;

Rosen, Neal ;

Sawyers, Charles L. .

CANCER CELL, 2011, 19 (05) :575-586

[5] Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study). [J].

De Bono, Johann S. ;

De Giorgi, Ugo ;

Massard, Christophe ;

Bracarda, Sergio ;

Kocak, Ivo ;

Font, Albert ;

Arija, Jose Angel Arranz ;

Shih, Kent C. ;

Radavoi, George Daniel ;

Yu, Wei ;

Chan, Wai Y. ;

Huang, Jian ;

Musib, Luna C. ;

Gendreau, Steven ;

Meng, Raymond D. ;

Patel, Premal H. ;

Maslyar, Daniel J. ;

Jinga, Vlore .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[6] TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort [J].

Demichelis, F. ;

Fall, K. ;

Perner, S. ;

Andren, O. ;

Schmidt, F. ;

Setlur, S. R. ;

Hoshida, Y. ;

Mosquera, J-M ;

Pawitan, Y. ;

Lee, C. ;

Adami, H-O ;

Mucci, L. A. ;

Kantoff, P. W. ;

Andersson, S-O ;

Chinnaiyan, A. M. ;

Johansson, J-E ;

Rubin, M. A. .

ONCOGENE, 2007, 26 (31) :4596-4599

[7] Distinct Genomic Aberrations Associated with ERG Rearranged Prostate Cancer [J].

Demichelis, Francesca ;

Setlur, Sunita R. ;

Beroukhim, Rameen ;

Perner, Sven ;

Korbel, Jan O. ;

LaFargue, Christopher J. ;

Pflueger, Dorothee ;

Pina, Cara ;

Hofer, Matthias D. ;

Sboner, Andrea ;

Svensson, Maria A. ;

Rickman, David S. ;

Urban, Alex ;

Snyder, Michael ;

Meyerson, Matthew ;

Lee, Charles ;

Gerstein, Mark B. ;

Kuefer, Rainer ;

Rubin, Mark A. .

GENES CHROMOSOMES & CANCER, 2009, 48 (04) :366-380

[8] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[9] PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate [J].

Ferraldeschi, Roberta ;

Rodrigues, Daniel Nava ;

Riisnaes, Ruth ;

Miranda, Susana ;

Figueiredo, Ines ;

Rescigno, Pasquale ;

Ravi, Praful ;

Pezaro, Carmel ;

Omlin, Aurelius ;

Lorente, David ;

Zafeiriou, Zafeiris ;

Mateo, Joaquin ;

Altavilla, Amelia ;

Sideris, Spyridon ;

Bianchini, Diletta ;

Grist, Emily ;

Thway, Khin ;

Lopez, Raquel Perez ;

Tunariu, Nina ;

Parker, Chris ;

Dearnaley, David ;

Reid, Alison ;

Attard, Gerhardt ;

de Bono, Johann .

EUROPEAN UROLOGY, 2015, 67 (04) :795-802

[10] Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer [J].

Hodgson, Myles C. ;

Shao, Long-jiang ;

Frolov, Anna ;

Li, Rile ;

Peterson, Leif E. ;

Ayala, Gustavo ;

Ittmann, Michael M. ;

Weigel, Nancy L. ;

Agoulnik, Irina U. .

CANCER RESEARCH, 2011, 71 (02) :572-582

← 1 2 3 →